Showing results (191-200 of 311) with videos related to

Sort By:
Pageof 32
Gynecologic Oncology|September 1, 1990
Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second lookM Bruzzone, L Repetto, S Chiara, et al.
Tumori|June 30, 1990
Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimensL Repetto, S Chiara, M Pace, et al.
La Radiologia Medica|July 1, 1992
[The results of definitive transcutaneous radiotherapy in the treatment of oropharyngeal neoplasms]G Gardani, F Valvo, R Kenda, et al.
Bone Marrow Transplantation|July 27, 2004
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell supportV Guarneri, C Bengala, C Orlandini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative GroupP F Conte, J Latreille, L Mauriac, et al.
Seminars in Oncology|June 1, 1994
Combination chemotherapy with vinorelbine, ifosfamide, and cisplatin: a phase II study in stage IIIB-IV non-small cell lung cancerE Baldini, C Tibaldi, A Chella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factorsA Gennari, B Salvadori, S Donati, et al.
The Journal of Urology|August 1, 1996
The effect of prepubertal androgen exposure on adult penile lengthR S Sutherland, B A Kogan, L S Baskin, et al.
Breast Cancer Research and Treatment|July 1, 1988
Cisplatin and 5-fluorouracil in refractory breast cancer patients: a phase II studyD Amoroso, P Pronzato, G Bertelli, et al.
British Journal of Cancer|November 27, 2001
Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC)E Baldini, A Ardizzoni, T Prochilo, et al.
Pageof 32